

HIV, HBV, and HCV Molecular Epidemiology Among Trans (Transvestites, Transsexuals, and Transgender) Sex Workers in Argentina

Mauricio Carobene,^{1,2*} Federico Bolcic,³ María Sol Dos Ramos Farías,^{1,2} Jorge Quarleri,^{1,2} and María Mercedes Ávila^{1,2}

¹Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), University of Buenos Aires, Buenos Aires Province, Argentina

²National Research Council (CONICET), Buenos Aires Province, Argentina

³School of Medicine, National University of Comahue, Rio Negro, Argentina

Commercial sex work is frequent among male-to-female transvestites, transsexuals and transgenders in Argentina, leading to high susceptibility to HIV, HBV, and HCV among other sexually transmitted infections. In a global context of scarce data on the trans sex workers population, this study was aimed to study the genomic characterization of these viruses. Plasma presence of HIV, HBV, and HCV genomic material was evaluated in samples from 273 trans sex workers. Genomic sequences of HIV-*gag*, *pol*, and *vif-vpu* genes, HBV-S gene, and HCV-5'UT and NS5B genes were obtained. Molecular characterization involved phylogenetic analysis and several in silico tools. Resistance-associated mutations in HIV and HBV *pol* genes were also analyzed. The HIV genomic characterization in 62 trans sex workers samples showed that 54.8% of the isolates corresponded to BF intersubtype recombinants, and 38.7% to subtype B. The remaining were classified as subtypes C (4.8%) and A (1.6%). HBV and HCV co-infection prevalence among HIV positive trans sex workers yielded rates of 3.2% and 6.5% respectively. Drug resistance-associated mutations were found in 12/62 (19%) HIV *pol* sequences, but none among HBV. Based on phylogenetic relationships, HIV isolates characterized as subtypes BF and B appeared intermingled with those from other high-risk groups. Despite trans sex workers declared not to have received antiviral treatment, complex drug resistance-associated mutation patterns were found in several HIV isolates. Planned prevention, screening, and treatment are needed to reduce further transmission and morbidity. **J. Med. Virol.** 86:64–70, 2014.

© 2013 Wiley Periodicals, Inc.

KEY WORDS: HIV; trans sex workers; viral hepatitis

INTRODUCTION

Commercial sex work is a high-risk activity that renders individuals at an increased risk of infection with HIV, HCV, HBV, and several other sexually transmitted infections [McKeganey, 1994; Talbott, 2007; Giami and Le Bail, 2011]. Thus, sex workers require special attention from epidemiological surveillance systems and public health agencies worldwide.

In Argentina, male-to-female transvestites, transsexuals and transgenders (collectively referred to as trans) sex workers are highly vulnerable and marginalized populations. As shown in our previous study focused on trans sex workers in Argentina, a high prevalence of sexually transmitted infections was found in this study population [Dos Ramos Farías et al., 2011]. Of note, the prevalence of HIV (34.1%), HBV (40.2%) and *Treponema pallidum* (50.4%) infections was alarmingly high, as was the incidence of HIV (10.7 per 100 person-year) infection, while the prevalence of HCV was 4.5%. The HIV prevalence observed was associated with a variety of factors such as commercial sex work, low level of education and strong social stigma and discrimination [Barreda, 2006; Dos Ramos Farías et al., 2011].

Grant sponsor: National Research Council (CONICET) Argentina; Grant number: PIP 112-200801-01773.; Grant sponsor: Global Fund (Sub-project); Grant number: 112.

The authors do not have any commercial or other association that might pose a conflict of interest.

*Correspondence to: Mauricio Carobene, PhD, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, Piso 11, C1121ABG, Buenos Aires, Argentina. E-mail: mcarobene@gmail.com

Accepted 21 August 2013

DOI 10.1002/jmv.23805

Published online 12 October 2013 in Wiley Online Library (wileyonlinelibrary.com).

The extensive diversity of HIV, HBV, and HCV represents a challenge for vaccine development and effectiveness [Taylor et al., 2008; Klenerman and Gupta, 2012; Lai et al., 2012]. It has been shown that besides prevention and diagnosis, performing genetic characterization studies is also relevant in the clinical context, since genotypes/subtypes can have an impact on treatment efficacy and severity of liver disease [Asselah et al., 2010; Wainberg and Brenner, 2010; Kim et al., 2011], as well as transmission and disease progression rates [Scott and Gretch, 2007; Tebit et al., 2007; Pujol et al., 2009].

As a result of the limited inclusion of trans sex workers in surveillance systems [Tsakris et al., 1997; Spizzichino et al., 2001; Bauer et al., 2012], and because of scarce data on HIV, HBV, and HCV genomic characterization among this population in the global context [Gutierrez et al., 2004], the present study was aimed to fully characterize HIV, HBV, and HCV variants circulating in trans sex workers from Argentina at the molecular level.

MATERIALS AND METHODS

Study Subjects and Plasma Samples

Frozen plasma samples from 273 trans sex workers obtained during a cross-sectional study conducted from October 2006 to December 2009 in five densely populated cities of Argentina (Buenos Aires, La Plata, Córdoba, Rosario, and Santiago del Estero) were studied [Dos Ramos Farias et al., 2011]. Most participants were young (mean age 29 years old, IQR 24–35), and nearly half of them had not completed high school (123 out of 273). The study population included individuals born in Argentina ($n=259$), Peru ($n=8$), Paraguay ($n=5$), and Ecuador ($n=1$). One third of the participants reported irregular use of condom mainly when engaged in commercial sex work with clients who offer them more money, evidencing higher rates of unsafe sex practices, even though they had a good general knowledge of HIV transmission routes. Regarding condom use with stable partners, as reported in female sex workers, this was generally irregular.

HIV infection diagnosis involved two screening techniques: ELISA (Enzygnost Anti-HIV 1/2 Plus ELISA, Dade Behring, Marburg, Germany) and particle agglutination (Fujirebio Diagnostics, Tokyo, Japan). Positive samples were confirmed subsequently by Western blot (New LAV Blot I, Bio-Rad Laboratories, WA). HBV infection markers such as surface antigen (HBsAg) and anti-core antibody (anti-HBc) were determined by ELISA (HBsAg (V2) Abbott AxSYM System, Core AxSYM System Abbott, Wiesbaden, Germany). For epidemiological purposes, a sample was considered HBV-positive if at least one of these markers was reactive. In order to determine HCV infection, anti-HCV antibodies were tested by ELISA (HCV version V3.0, Abbott AxSYM System, Wiesbaden, Germany). Those plasma samples posi-

tive for HIV by Western blot, reactive for HBsAg and/or anti-HBc, or with anti-HCV results, were selected for HIV-RNA, HBV-DNA, and/or HCV-RNA detection, respectively.

This study was performed in compliance with international and national ethical guidelines for biomedical research involving human subjects [CIOMS, 2002]. The research project was approved by Nexo AC Institutional Biomedical Review Board (IRB 5349), and carried out under all federal regulations governing the protection of human subjects in research.

HIV-RNA, HBV-DNA, and HCV RNA Isolation, PCR, and Sequencing

HBV DNA was obtained from 200 μ l of plasma using a commercial kit (QIAamp DNA mini kit, Qiagen, Hilden, Germany) according to the manufacturer's instructions, and used as a template for a nested PCR amplification of the HBV S genomic region (585 nt, from nucleotide 203–787), as described previously [Quarleri et al., 2007].

HIV and HCV viral genomes were obtained from plasma samples using a commercial kit (QIAamp Viral RNA kit, Qiagen), and used as template for reverse transcription and PCR amplifications.

For HIV, amplicons from partial *pol* (1,496 bp, positions 2253–3749), *gag* (1,097 bp, positions 1231–2328) and *vif-vpr-tat* (314 bp, positions 5545–5859, HXB2 numbering, GenBank accession number K03455) coding sequences were obtained. PCR products were used as a template for double strand automated sequencing (ABI PRISM 3100 automated sequencer, Applied Biosystems, Foster City, CA and Big Dye Terminator sequencing kit, Amersham, Stockholm, Sweden).

Presence of HCV-RNA was first evaluated using reverse transcription (RT)-nested PCR amplification of the 5'untranslated region (5'UTR), as described elsewhere [Quarleri et al., 2000]. Positive HCV-RNA samples were further studied performing a PCR amplification of the NS5B gene as described previously [Laperche et al., 2005]. Briefly, cDNA was amplified by a heminested PCR, obtaining a 401-bp product that encompassed nucleotide positions 8245 and 8645 based on the standard numbering system [Choo et al., 1991]. DNA from purified PCR products (QIAquick PCR Purification Kit, Qiagen) was used as a template for double strand automated sequencing (ABI PRISM 3100 automated sequencer, Applied Biosystems and Big Dye Terminator sequencing kit, Amersham) as described elsewhere [Quarleri et al., 2004].

Phylogenetic Analysis

HIV *pol*, HBV-S, and HCV-NS5B nucleotide sequences were edited and assembled with Sequencer v.4.10.1 (Gene Codes).

For the HIV phylogenetic inference, 132 HIV *pol* reference sequences were retrieved from GenBank.

Among such references, 63 were previously characterized in Argentina from infected individuals with a well-defined risk of infection, including injecting drug users (n=22), men who have sex with men (n=3), women who have sex with men (n=10), heterosexual men (n=5), mother-to-child transmission (n=7), female sex workers (n=8), commercial sex workers (n=3), male sex workers (n=3) and unknown transmission route (n=2). Likewise, reference sequences for the various HBV and HCV genotypes/subtypes were obtained from GenBank and the European Hepatitis C database [Kuiken et al., 2005; Combet et al., 2007].

Multiple sequence alignment was achieved by the Mafft program [Kato et al., 2002, 2009]. Each viral nucleotide sequence dataset was input into phylogenetic studies and analyzed by Maximum Likelihood technique. For probabilistic analyses, the sequence evolution model was inferred by MrAIC [Nylander et al., 2004]. The model which best fitted the data was GTR+I+G. Maximum likelihood trees were inferred with PhyML version 3.0 [Guindon and Gascuel, 2003], using a BIONJ starting tree reordered by SPR in search of the tree space. Tree searches were performed as described elsewhere [Dilernia et al., 2008]. Shortly, cycles of random addition sequences plus tree-bisection-reconnection were followed by ratcheting, tree-drifting and tree fusing until no further improvement of tree lengths were observed. Phylogenetic grouping robustness was evaluated by bootstrap analysis using ML (1,000 replicates) with the PhyML software.

HIV and HBV Genotypic Drug Resistance Testing

In addition, HIV and HBV *pol* sequences were analyzed in search of resistance mutations using the Stanford University Calibrated Population Resistance Tool, HIV Drug Resistance Database (<http://sierra2.stanford.edu/sierra/servlet/JSierra>), and the HepSEQ-Research Database System website (http://www.hepseq.org/Public/Web_Front/main.php), respectively.

HIV, HBV, and HCV Genotyping Analysis

HIV *gag*, *pol* and *vif-vpr-tat* gene nucleotide sequences were used for subtype assignment and recombination analysis using SimPlot (version 2.5; Stuart Ray, <http://www.med.jhu.edu>), and the following tools available online: jumping profile Hidden Markov Model (jpHMM), and NCBI genotyping tool (<http://www.ncbi.nlm.nih.gov/projects/genotyping/formpage.cgi>).

HBV *pol* gene nucleotide sequences and HBV genotypes were defined using the Oxford HBV subtyping tool (<http://www.bioafrica.net/rega-genotype/html/citotoolhbv.html>) and the STAR genotyping tool (<http://www.vgb.ucl.ac.uk/starn.shtml>).

Similarly, HCV NS5B gene nucleotide sequences (400 bp, positions 8245–8645) were used for sub-

typing using tools available online: Oxford HCV subtyping (<http://www.bioafrica.net/regagenotype/html/subtypinghcv.html>) and NCBI viral genotyping (<http://www.ncbi.nlm.nih.gov/projects/genotyping/formpage.cgi>).

Statistical Analysis

Comparisons among proportions were analyzed by parametric (Student's *t* test) and non-parametric methods (Mann-Whitney *U* test). Univariate analyses were performed by Chi-square test or Fisher's exact test, according to the sample size. Statistical analyses were carried out using SPSS 15.0 (SPSS, Inc., Chicago, IL).

RESULTS

Prevalence of HIV, HBV, and HCV Infections Among Trans-Sex Workers

HIV infection was confirmed in 93/273 samples. HBV and HCV serology tests were performed in 264/273 individuals, and 106/264 and 12/264 samples exhibited serological markers associated with infection, respectively. It was not possible to determine the hepatitis serological status in nine patients due to the scarce sample material obtained. Seventy-five out of 106 HBV positive samples (HBsAg and/or anti-HBc reactive) exhibited anti-HBs antibodies and were assumed as samples from individuals who recovered from natural infection (resolved infection). Among the remaining 31 samples, only 3 (12%) were positive for HBV-DNA, and were subjected to genotypic characterization. In this group of samples, 25 and 6 samples corresponded to HBV-HIV coinfecting and HBV-monoinfecting, respectively, which represents a coinfection prevalence of 3.2%.

Samples in which only anti-HBc antibodies were detected could correspond to patients on the time gap between the disappearance of HBsAg and the appearance of anti-HBs antibodies, or be false positive.

HIV viral load (VL) was determined in the 93 HIV-infected trans sex workers, and 62 exhibited detectable viremia (≥ 50 copies/ml).

Regarding HCV, 6 out of 12 individuals exhibiting detectable anti-HCV antibodies and HCV-RNA were coinfecting with HIV, thus representing a coinfection prevalence of 6.5%. Only one HCV-monoinfecting individual had detectable HCV-RNA.

HIV, HBV, and HCV Genotyping and Phylogenetic Analysis

HIV genotyping analysis was performed by examining 3 genomic regions, as described in M&M, to minimize erroneous subtype assignment (Table I). Together with the phylogenetic analysis performed on *pol* sequences, this showed that 34 and 24 out of 62 samples corresponded to BF intersubtype recombinants (54.8%) and subtype B (38.7%), respectively. Three samples (1 from Ecuador and 2 from

TABLE I. HIV Subtype Assignment Based on Each Partial Gene Analyzed by Online Genotyping Tools and Simplot

gag	pol	vif-vpr-tat	Number of isolates (%)
B	B	B	24 (38.7)
F	BF	BF	5 (8.1)
F	BF	F	19 (30.1)
B	BF	BF	1 (1.6)
F	BF	B	2 (3.2)
F	F	F	1 (1.6)
BF	BF	BF	2 (3.2)
B	B	BF	2 (3.2)
BF	B	BF	1 (1.6)
B	B	F	1 (1.6)

Argentina) were ascribed to subtype C (4.8%) and one sample (from Peru) to subtype A (1.6%). HIV *pol* sequences did not form any statistically significant cluster during the phylogenetic analysis, appearing intermingled with other HIV isolates identified previously in individuals with other risks associated with infection (Fig. 1) (GenBank accession numbers: JX847141–JX847202). A complete coincidence for HIV-subtype assignment was found between the phylogenetic inference method and the analysis carried out with genotyping tools. The frequencies of subtype B and BF intersubtype recombinant variants found in Argentina among trans sex workers exhibit statistically significant differences when compared with those reported previously among men who have sex with men and heterosexuals ($P < 0.05$), but this significance was not observed when compared with female sex workers ($P > 0.05$).

Primary drug resistance-associated mutations (to NRTIs, NNRTIs, and PIs) were found in 12 out of 62 (19%) HIV *pol* sequences (Table II).

The HBV genomic characterization based on S gene nucleotide sequences of the samples with detectable HBV-DNA showed coincident results using both phylogenetic and online genotyping tools. Two were ascribed to genotype A2 and one to genotype C (Fig. 1). No drug resistance-associated mutations were identified when the analysis of HBV *pol* gene was carried out.

HCV genotyping results based on NS5B gene sequences were identical using phylogenetic and online typing analyses. Viral variants in HCV RNA-positive samples ($n = 7$) were ascribed to genotype 1a ($n = 2$), 1b ($n = 1$), 3a ($n = 2$), 4a ($n = 1$), and 4d ($n = 1$).

DISCUSSION

Trans sex worker individuals have become one of the fastest growing populations within the HIV pandemic [Sebastian, 1999; Lombardi and van Servellen, 2000]. This marginalized population is difficult to study, mainly due to their behavior and frequent migrations [Spizzichino et al., 2001; Perrin et al., 2003; Wright, 2003; The United Nations

Population Fund, 2011]. Transsexualism is a worldwide phenomenon, not limited to western societies, and this is mainly related to surgical techniques and accessibility to surgical interventions which improved progressively.

In Latin America, commercial sex work frequently represents a way of procuring financial resources for survival among trans people. Consequently, epidemiological surveillance of sexually transmitted infections in this population is a topic of high relevance in the context of public health.

To our knowledge, the present study is the first to address the HIV, HBV, and HCV genomic characterization in trans sex workers from Argentina, and to a lesser extent, from other Latin American countries (i. e., people born in Peru, Paraguay and Ecuador that live and work in Argentina).

Despite the high prevalence of sexually transmitted infections found among trans sex workers, the genomic characterization of HIV reveals the presence of viral variants that prevail in other high-risk groups, and in the general population. The HIV subtypes B and BF intersubtype recombinants characterized in Argentinean trans sex workers have been found in other at-risk populations. Regarding frequencies, a dichotomy was reported about viruses found in the heterosexual community vs. the homosexual community, depicting two independent HIV epidemics in the same geographic region [Avila et al., 2002; Dileria et al., 2007a]. Here, subtype B and BF intersubtype recombinant frequencies found among trans sex workers appear distinguishable from these two, but similar to the frequencies found in female sex workers. These two at-risk groups predominantly engage in commercial sex with male customers. Nevertheless, the phylogenetic relationship established among HIV isolates showed no evidence of a clustering phenomenon according to the related infection risk. Taking this into account, we hypothesize that trans sex workers could play a role in bridging the gap between men who have sex with men and heterosexual populations. In order to draw a more definitive conclusion in this matter, further studies on well-defined trans sex worker populations, their clients and related individuals are needed.

This study shows that BF intersubtype recombinant variants were most frequently found among trans sex workers followed by subtype B variants. Subtypes C and A, detected previously in Argentina [Gomez-Carrillo et al., 2004; Pando et al., 2006, 2007; Segura et al., 2007; Dileria et al., 2007a] were also present but in a low frequency. As shown in the results section, subtype C was found in samples from 2 Argentinean patients and 1 from a patient born in Ecuador, while the sample harboring the subtype A variant was obtained from a patient born in Peru. This result highlights the role of migration in the HIV epidemic dynamics.

All participants reported neither being aware of their serological status nor having received antiviral




Fig. 1. Maximum-likelihood analysis of HIV pol gene (upper tree), HBV S gene (middle tree), and HCV NS5B gene (lower tree) nucleotide sequences from transsexual workers (black dots) obtained by direct sequencing. The HIV, HBV, and HCV reference sequences were retrieved from GenBank and Hepatitis C database and are indicated by their accession number. Among the HIV reference sequences, those previously obtained in Argentinean individuals are also identified with the infection associated-risk (see M&M). The phylogenetic trees topology were evaluated by bootstrap analysis (1,000 replicates) and significant values are shown at each node. The subtypes/genotypes for each virus are indicated in bold capital letters and lines. The ruler shows the branch length for a pairwise distance equal to 0.1.

TABLE II. Drug Resistance-Associated Mutations Found in TSW Samples

Sample subtype	Resistance mutations associated to		
	NRTI	NNRTI	PI
B	—	K103N	—
B	—	Y181C	—
BF	M184V, T215Y	K103N	V82A
BF	M184V	K103N	M46L, I54V, V82A
BF	M184V	K103N	—
BF	—	—	M46I, I54V, V82A
BF	D67N, K70R, T215E, K219Q	K101E, G190S	—
BF	—	G190A	—
BF	—	—	V82F, L90M
BF	M41L, L74V, M184V, T215Y	K101E, Y181C, G190A	I54V, V82A, L90M
BF	D67N	—	—
C	D67N, T215S, K219E	—	—

Corresponding subtypes and drug class are shown.

treatment. Nevertheless, our results on viral load determinations raised the question if some of them could have been taking medication without reporting it. In addition, some drug resistance mutation patterns observed indicate that they could have provided false information or that infection with high resistant HIV variants may have occurred. The fact that primary resistance mutations were found in 20% of the samples may hamper future treatment options and prognosis, while increasing the possibility of transmission of drug resistant variants to the uninfected population. It is important to highlight that drug-resistance surveillance among newly HIV-1 diagnosed individuals in Argentina has been shown previously to be between 4% and 9%, and up to 33% depending on the study population [Vignoles et al., 2007; Dilernia et al., 2007b; Pando et al., 2011].

Regarding the HBV and HCV genomic characterization, our study allowed us to determine the presence of different genotypes in this population. Nevertheless, the sample size is too small to draw a conclusion.

In summary, the trans sex worker population from Argentina exhibits the highest HIV prevalence among at risk groups, where HBV and HCV coinfection is also detected. The HIV molecular characterization reflects a similar scene to that observed before in other at risk groups. Thus, the trans sex worker group may play a central role as a niche for different sexually transmitted infections, especially HIV. All these conditions distinguish this group from other populations studied previously in Argentina, and highlight the need for well-designed periodic surveillance studies of sexually transmitted diseases in such populations, which will allow the early recognition of the increase in the rate of some infections and future changes in viral diversity, as well as the design of specific early interventions. Fully understanding the genetic diversity of these human pathogens and its implications for prevention, vaccine development, and chemotherapy will allow the control of the epidemic.

REFERENCES

- Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, Saadoun D, Soumelis V, Marcellin P. 2010. Hepatitis C: Viral and host factors associated with non-response to pegylated interferon plus ribavirin. *Liver Int* 30:1259–1269.
- Avila MM, Pando MA, Carrion G, Peralta LM, Salomon H, Carrillo MG, Sanchez J, Maulen S, Hierholzer J, Marinello M, Negrete M, Russell KL, Carr JK. 2002. Two HIV-1 epidemics in Argentina: Different genetic subtypes associated with different risk groups. *J Acquir Immune Defic Syndr* 29:422–426.
- Barreda V. 2006. Prevención de VIH y travestismo: un escenario de categorías en crisis. In: Cáceres C, Careaga G, Frasca T, Pecheny M, editors. *Sexualidad, Estigma y Derechos Humanos. Desafíos para el acceso a la salud en América Latina*: Lima, FASPA/UPCH. ISBN 9972-806-25-1.
- Bauer GR, Travers R, Scanlon K, Coleman TA. 2012. High heterogeneity of HIV-related sexual risk among transgender people in Ontario, Canada: A province-wide respondent-driven sampling survey. *BMC Public Health* 12:292.
- Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, Gallegos D, Coit CD, Medina-Selby A, Barr PJ, Weiner AJ, Bradley DW, Kuo G, Houghton M. 1991. Genetic organization and diversity of the hepatitis C virus. *Proc Natl Acad Sci USA* 88:2451–2455.
- Combet C, Garnier N, Charavay C, Grando D, Crisan D, Lopez J, Dehne-Garcia A, Geourjon C, Bettler E, Hulo C, Le Mercier P, Bartenschlager R, Diepolder H, Moradpour D, Pawlotsky JM, Rice CM, Trepo C, Penin F, Deleage G. 2007. euHCVdb: The European hepatitis C virus database. *Nucleic Acids Res* 35:D363–D366.
- Council for International Organizations of Medical Sciences. 2002. International ethical guidelines for biomedical research involving human subjects. *Bull Med Ethics* 182:17–23.
- Dilernia DA, Gomez AM, Lourtau L, Marone R, Losso MH, Salomon H, Gomez-Carrillo M. 2007a. HIV type 1 genetic diversity surveillance among newly diagnosed individuals from 2003 to 2005 in Buenos Aires, Argentina. *AIDS Res Hum Retroviruses* 23:1201–1207.
- Dilernia DA, Lourtau L, Gomez AM, Ebenstejin J, Toibaro JJ, Bautista CT, Marone R, Carobene M, Pampuro S, Gomez-Carrillo M, Losso MH, Salomon H. 2007b. Drug-resistance surveillance among newly HIV-1 diagnosed individuals in Buenos Aires, Argentina. *AIDS* 21:1355–1360.
- Dilernia DA, Jones L, Rodriguez S, Turk G, Rubio AE, Pampuro S, Gomez-Carrillo M, Bautista CT, Deluchi G, Benetucci J, Lasala MB, Lourtau L, Losso MH, Perez H, Cahn P, Salomon H. 2008. HLA-driven convergence of HIV-1 viral subtypes B and F toward the adaptation to immune responses in human populations. *PLoS ONE* 3:e3429.
- Dos Ramos Farias MS, Garcia MN, Reynaga E, Romero M, Vaulet ML, Fermepin MR, Toscano MF, Rey J, Marone R, Squiquera L, Gonzalez JV, Basiletti J, Picconi MA, Pando MA, Avila MM. 2011. First report on sexually transmitted infections among trans (male to female transvestites, transsexuals, or transgender) and male sex workers in Argentina: High HIV, HPV, HBV, and syphilis prevalence. *Int J Infect Dis* 15:e635–e640.

- Giami A, Le Bail J. 2011. HIV infection and STI in the trans population: A critical review. *Rev Epidemiol Sante Publique* 59:259–268.
- Gomez-Carrillo M, Quarleri JF, Rubio AE, Carobene MG, Dileria D, Carr JK, Salomon H. 2004. Drug resistance testing provides evidence of the globalization of HIV type 1: A new circulating recombinant form. *AIDS Res Hum Retroviruses* 20:885–888.
- Guindon S, Gascuel O. 2003. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. *Syst Biol* 52:696–704.
- Gutierrez M, Tajada P, Alvarez A, De Julian R, Baquero M, Soriano V, Holguin A. 2004. Prevalence of HIV-1 non-B subtypes, syphilis, HTLV, and hepatitis B and C viruses among immigrant sex workers in Madrid, Spain. *J Med Virol* 74:521–527.
- Katoh K, Misawa K, Kuma K, Miyata T. 2002. MAFFT: A novel method for rapid multiple sequence alignment based on fast Fourier transform. *Nucleic Acids Res* 30:3059–3066.
- Katoh K, Asimenos G, Toh H. 2009. Multiple alignment of DNA sequences with MAFFT. *Methods Mol Biol* 537:39–64.
- Kim BK, Revill PA, Ahn SH. 2011. HBV genotypes: Relevance to natural history, pathogenesis and treatment of chronic hepatitis B. *Antivir Ther* 16:1169–1186.
- Klenerman P, Gupta PK. 2012. Hepatitis C virus: Current concepts and future challenges. *QJM* 105:29–32.
- Kuiken C, Yusim K, Boykin L, Richardson R. 2005. The Los Alamos hepatitis C sequence database. *Bioinformatics* 21:379–384.
- Lai MW, Lin TY, Tsao KC, Huang CG, Hsiao MJ, Liang KH, Yeh CT. 2012. Increased seroprevalence of HBV DNA with mutations in the S gene among individuals greater than 18 years old after complete vaccination. *Gastroenterology* 143:400–407.
- Laperche S, Le Marrec N, Girault A, Bouchardeau F, Servant-Delmas A, Maniez-Montreuil M, Gallian P, Levayer T, Morel P, Simon N. 2005. Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection. *J Clin Microbiol* 43:3877–3883.
- Lombardi EL, van Servellen G. 2000. Correcting deficiencies in HIV/AIDS care for transgendered individuals. *J Assoc Nurses AIDS Care* 11:61–69.
- McKeganey NP. 1994. Prostitution and HIV: What do we know and where might research be targeted in the future? *AIDS* 8:1215–1226.
- Nylander JA, Ronquist F, Huelsenbeck JP, Nieves-Aldrey JL. 2004. Bayesian phylogenetic analysis of combined data. *Syst Biol* 53:47–67.
- Pando MA, Eyzaguirre LM, Segura M, Bautista CT, Marone R, Ceballos A, Montano SM, Sanchez JL, Weissenbacher M, Avila MM, Carr JK. 2006. First report of an HIV-1 triple recombinant of subtypes B, C and F in Buenos Aires, Argentina. *Retrovirology* 3:59.
- Pando MA, Eyzaguirre LM, Carrion G, Montano SM, Sanchez JL, Carr JK, Avila MM. 2007. High genetic variability of HIV-1 in female sex workers from Argentina. *Retrovirology* 4:58.
- Pando MA, Gomez-Carrillo M, Vignoles M, Rubio AE, dos Ramos Farias MS, Vila M, Rossi D, Ralon G, Marone R, Reynaga E, Sosa J, Torres O, Maestri M, Avila MM, Salomon H. 2011. Incidence of HIV type 1 infection, antiretroviral drug resistance, and molecular characterization in newly diagnosed individuals in Argentina: A Global Fund Project. *AIDS Res Hum Retroviruses* 27:17–23.
- Perrin L, Kaiser L, Yerly S. 2003. Travel and the spread of HIV-1 genetic variants. *Lancet Infect Dis* 3:22–27.
- Pujol FH, Navas MC, Hainaut P, Chemin I. 2009. Worldwide genetic diversity of HBV genotypes and risk of hepatocellular carcinoma. *Cancer Lett* 286:80–88.
- Quarleri JF, Robertson BH, Mathet VL, Feld M, Espinola L, Requeijo MP, Mando O, Carballal G, Oubina JR. 2000. Genomic and phylogenetic analysis of hepatitis C virus isolates from Argentine patients: A six-year retrospective study. *J Clin Microbiol* 38:4560–4568.
- Quarleri JF, Rubio A, Carobene M, Turk G, Vignoles M, Harrigan RP, Montaner JS, Salomon H, Gomez-Carrillo M. 2004. HIV type 1 BF recombinant strains exhibit different pol gene mosaic patterns: Descriptive analysis from 284 patients under treatment failure. *AIDS Res Hum Retroviruses* 20:1100–1107.
- Quarleri J, Moretti F, Bouzas MB, Laufer N, Carrillo MG, Giuliano SF, Perez H, Cahn P, Salomon H. 2007. Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B. *AIDS Res Hum Retroviruses* 23:525–531.
- Scott JD, Gretch DR. 2007. Molecular diagnostics of hepatitis C virus infection: A systematic review. *JAMA* 297:724–732.
- Sebastian C. 1999. Transgenderism and the AIDS epidemic. *Posit Aware* 10:57.
- Segura M, Sosa Estani S, Marone R, Bautista CT, Pando MA, Eyzaguirre L, Sanchez JL, Carr JK, Montano SM, Weissenbacher M, Avila MM. 2007. Buenos Aires cohort of men who have sex with men: Prevalence, incidence, risk factors, and molecular genotyping of HIV type 1. *AIDS Res Hum Retroviruses* 23:1322–1329.
- Spizzichino L, Zaccarelli M, Rezza G, Ippolito G, Antinori A, Gattari P. 2001. HIV infection among foreign transsexual sex workers in Rome: Prevalence, behavior patterns, and seroconversion rates. *Sex Transm Dis* 28:405–411.
- Talbott JR. 2007. Size matters: The number of prostitutes and the global HIV/AIDS pandemic. *PLoS ONE* 2:e543.
- Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. 2008. The challenge of HIV-1 subtype diversity. *N Engl J Med* 358:1590–1602.
- Tebit DM, Nankya I, Arts EJ, Gao Y. 2007. HIV diversity, recombination and disease progression: How does fitness “fit” into the puzzle? *AIDS Rev* 9:75–87.
- The United Nations Population Fund U. 2011. Addressing migration and mobility in the context of HIV and sex work. Chapter six. Building partnerships on HIV and sex work. Report and recommendations from the first Asia and the Pacific Regional Consultation on HIV and Sex Work: 33–38.
- Tsakris A, Kyriakis KP, Chryssou S, Papoutsakis G. 1997. Infection by hepatitis B and C virus in female and transsexual Greek prostitutes with serological evidence of active syphilis. *Int J STD AIDS* 8:697–699.
- Vignoles M, Barboni G, Agosti MR, Quarleri J, Garcia MK, Giraudi V, Ayala SG, Salomon H. 2007. High frequency of primary mutations associated with antiretroviral drug resistance in recently diagnosed HIV-infected children. *Antivir Ther* 12:1133–1137.
- Wainberg MA, Brenner BG. 2010. Role of HIV subtype diversity in the development of resistance to antiviral drugs. *Viruses* 2:2493–2508.
- Wright ER. 2003. Travel, tourism, and HIV risk among older adults. *J Acquir Immune Defic Syndr* 33:S233–S237.